What the FDA labels say about taking them together
Dihydroergotamine and fluvoxamine
Dihydroergotamine's FDA label of March 6, 2025 names fluvoxamine in its drug interactions section; the fluvoxamine labels PlainMeds reads (2) do not name dihydroergotamine. The dihydroergotamine label: “Selective Serotonin Reuptake Inhibitors Weakness, hyperreflexia, and incoordination have been reported rarely when 5-HT 1 agonists have been co-administered with selective serotonin reuptake inhibitors.”
Check it at the source: the dihydroergotamine FDA label on DailyMed (effective March 6, 2025, Oceanside Pharmaceuticals); the fluvoxamine FDA label on DailyMed (effective June 27, 2026, Zydus Pharmaceuticals USA Inc.).
What does the dihydroergotamine label say about fluvoxamine?
Dihydroergotamine label, drug interactionsSSRI’s Weakness, hyperreflexia, and incoordination have been reported rarely when 5HT 1 agonists have been coadministered with SSRI’s (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline).
Dihydroergotamine label, warningsLess potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.
Source: FDA drug label (Trudhesa, NDA213436), Impel Pharmaceuticals LLC, effective September 3, 2026 (SPL set b81397b0-910d-4eb4-8fee-a9a3c9d94d63), via openFDA
Source: FDA drug label (Atzumi, NDA217901), Satsuma Pharmaceuticals, Inc., effective June 22, 2026 (SPL set 0982a44a-dc0c-75c0-e063-6394a90a6d6c), via openFDA
Source: FDA drug label (Dihydroergotamine Mesylate), NDA020148 (Bausch), as published by Oceanside Pharmaceuticals, effective March 6, 2025 (SPL set 977de209-c53a-4cb4-9f3f-1e850600a9dc), via openFDA; the full label on DailyMed
What does the fluvoxamine label say about dihydroergotamine?
Fluvoxamine's label (effective June 27, 2026) and its 1 other brand-application label do not name dihydroergotamine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Fluvoxamine maleate extended-release), Zydus Pharmaceuticals USA Inc., effective June 27, 2026 (SPL set 6c71d4f6-54b5-4d3a-8d2f-b7773c92c32e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dihydroergotamine | Fluvoxamine | |
|---|---|---|
| Labeled for | Migraine | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $29.44 per mL 4 mg/mL nasal spray | $4.08 per capsule 100 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once